Gilead has a small molecule, oral GLP-1 agonist (GS-4571) currently recruiting for phase I clinical trials, with results not expected until mid-2026
Its key features include rapid absorption, precision dosage, and reliable formulation in a sterile liquid form
Blood sugar is stabilized: Semaglutide helps regulate blood sugar by increasing insulin release when blood sugar rises and lowering glucagon, which helps prevent spikes
And the caloric restriction from medication means additional restriction from fasting requires more careful calibration
[00:48:58] Even if you and I showed up as a team and said we're going to get to work on this woman with our knowledge base, which would be a dream, I think, for any woman in the middle age, we still couldn't pull them out sufficiently
And I think its probably both